Articles
Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder
- Journal/Conference:
- Neurology and Therapy
- Author(s):
- Cree, B.A.; Greenberg, B.; Cameron, C.; Weinshenker, B.G.
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Immune
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry
- Journal/Conference:
- Leukemia & Lymphoma
- Author(s):
- Buckstein, R.; Chodirker, L.; Yee, K.W.; Geddes, M.; Leitch, H.A.; Christou, G.; Banerji, V.; Leber, B.; Khalaf, D.; St-Hilaire, E.; Finn, N.;' Nevill, T.; Keating, M.; Storring, J.; Parmentier, A.; Thambipillai, A.; Tang, D.; Westcott, C.; Cameron, C.; Spin, P.
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Oncology
P45 Internal, External, and Cross-Validation of the DEDUCE Model, a Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes
- Journal/Conference:
- Value in Health
- Author(s):
- Castro, J.C.; De Pouvourville G, Greenberg D, Harris S, Jendle J, Shaw JE, Gullen F, Szafranski K
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Diabetes
P45 Internal, External, and Cross-Validation of the DEDUCE Model, a Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes
- Journal/Conference:
- Value in Health
- Author(s):
- Castro, J.C.; De Pouvourville G, Greenberg D, Harris S, Jendle J, Shaw JE, Gullen F, Szafranski K
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Diabetes
Unmet Need in People with Psoriasis and Skin of Color in Canada and the United States
- Journal/Conference:
- Dermatology and Therapy
- Author(s):
- Yadav G, Yeung J, Miller-Monthrope Y, Lakhani O, Drudge C, Craigie S, Mendell A, Park-Wyllie L.
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Psoriasis
Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.
- Journal/Conference:
- Pharmacoecon Open
- Author(s):
- Baharnoori M, Bhan V, Clift F, Thomas K, Mouallif S, Adlard N, Cooney P, Blanchette F, Patel BP, Grima D.
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Multiple Sclerosis, Nervous System
“Economic analysis of n-butyl cyanoacrylate compared with ethylene vinyl alcohol copolymer liquid embolic embolization of brain arteriovenous malformations (bAVMs) from a US hospital perspective”
- Journal/Conference:
- Interventional Neuroradiology
- Author(s):
- Sudhakar R. Satti , Emilie Kottenmeier, Alia Khaled, George W.J. Wright and Heather L. Cameron
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Brain
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
- Journal/Conference:
- Americal Journal of Cardiovascular Drugs
- Author(s):
- Rozenbaum, M.H.; Tran, D.; Bhambri, R.; Nativi-Nicolau, J.
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Cardiovascular
An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective
- Journal/Conference:
- BMC Health Services Research Morgans AK, Hutson T, Guan AKD, Garcia D, Zhou A, et al. An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective. BMC Health Serv Res. 2022 Jul 14;22(1):916. doi: 10.1186/s12913-022-08274-x https://pubmed.ncbi.nlm.nih.gov/35836170/
- Author(s):
- Morgans AK, Hutson T, Guan AKD, Garcia D, Zhou A, Drea E, Vogelzang NJ An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective Oncology BMC Health Services Research Morgans AK, Hutson T, Guan AKD, Garcia D, Zhou A, et al. An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective. BMC Health Serv Res. 2022 Jul 14;22(1):916. doi: 10.1186/s12913-022-08274-x https://pubmed.ncbi.nlm.nih.gov/35836170/
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Oncology
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
- Journal/Conference:
- ASH 2022
- Author(s):
- Fonseca, R.; Tran, D.; Rosta, E.; Laidlaw, A.; Rai, M.; Duran, J.; Ammann, E.M.
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Blood, Oncology